IGF1 and type 1 diabetes mellitus: The study showed that a single subcutaneous injection of recombinant human IGF-1 (40 mg/kg) resulted in elevated levels of IGF-1, reduced overnight secretion of GH, and declined insulin necessities in 9 pubertal adolescents with T1D [21].